Global Ringworm Treatment Market Size To Grow USD 21.3 Billion By 2032 | CAGR of 4.36%
SPHERICAL INSIGHTS LLP
SPHERICAL INSIGHTS LLP

The Global Ringworm Treatment Market Size was valued at USD 13.9 Billion in 2022 and the Worldwide Global Ringworm Treatment Market size is expected to reach USD 21.3 Billion by 2032. according to a research report published by Spherical Insights & Consulting, Companies Covered: Perrigo Company plc, Novartis AG, GlaxoSmithKline Plc, Teva Pharmaceuticals, Inc., Taro Pharmaceutical Industries Ltd., Glenmark Pharmaceuticals Inc., Avik Pharma, Actiza Pharmaceutical, Chempro Group India, Merck & Co., Inc. and Other key vendors.

New York, United States, Nov. 15, 2023 (GLOBE NEWSWIRE) -- The Global Ringworm Treatment Market Size is to grow from USD 13.9 Billion in 2022 to USD 21.3 Billion by 2032, at a Compound Annual Growth Rate (CAGR) of 4.36% during the forecast period.

Get a Sample PDF Brochure: https://www.sphericalinsights.com/request-sample/2486

Ringworm is a common fungal infection of the skin. Tinea is the medical term for ringworm. The illness is caused by dermatophytes, which are skin fungi. Ringworm can cause scaly, red, and circular areas of skin. It can also cause scalp scaling, irritation, blisters, and spot hair loss. The infection can spread to the scalp, foot, beard, and crotch area. Ringworm is very contagious and may be spread by animals. Certain antifungal and over-the-counter medications can effectively treat the condition. In addition, several reasons have contributed to the growth of ringworm instances, including increased urbanization, congested living circumstances, insufficient sanitation, and an increase in the number of immunocompromised people. Lifestyle changes, such as greater engagement in sports and leisure activities, have also raised the chance of transmission.

The availability of over-the-counter treatments for fungal infections, as well as increasing awareness of ringworm infections and their symptoms, aided market growth. Moreover, public education and healthcare measures have increased people's awareness of the early signs of ringworm, encouraging them to seek treatment as soon as possible. This improved knowledge has aided not just patient outcomes but also market expansion in general. Furthermore, Drug resistance to conventional antifungal medications may restrain market growth. The widespread and frequently not appropriate use of antifungal drugs has led to the development of drug-resistant strains of the fungus that causes ringworm infections. Standard antifungal medications become less effective when resistant strains emerge, resulting in treatment failures. This may hurt the sales of some drugs used to treat ringworm infections.